Effects of pharmaceuticals on membrane bioreactor: Review on membrane fouling mechanisms and fouling control strategies.

Pharmaceuticals have become contaminants of emerging concern due to their toxicity towards aquatic life and pseudo persistent nature in the environment. Membrane bioreactor (MBR) is one such technology that has the potential to act as a barrier against the release of pharmaceuticals into the environment. Fouling is the deposition of the constituents of the mixed liquor on the membrane surface and it limit the world-wide applicability of MBRs. To remove foulant layer, aggressive chemicals and extra cost consideration in terms of energy are required. Extracellular polymeric substances (EPS) and soluble microbial products (SMP) are recognized as principal foulants. Presence of pharmaceuticals has been found to increase the fouling in MBRs. Fouling aggravates in proportion to the concentration of pharmaceuticals. Pharmaceuticals exert chemical stress in microbes, hence forcing them to secrete more EPS/SMP. Pharmaceuticals alter the composition of the foulants and affect microbial metabolism, thereby inflicting direct/indirect effects on fouling. Pharmaceuticals have been found to increase or decrease the size of sludge flocs, however the exact mechanism that govern the floc size change is yet to be understood. Different techniques such as coupling advanced oxidation processes with MBR, adding activated carbon, bioaugmenting MBR with quorum quenching strains have shown to reduce fouling in MBRs treating pharmaceutical wastewater. These fouling mitigation techniques work on reducing the EPS/SMP concentration, thereby alleviating fouling. The present review provides a comprehensive understanding of the effects induced by pharmaceuticals in the activated sludge characteristics and identifying the fouling mechanism. Furthermore, significant knowledge gaps and recent advances in fouling mitigation strategies are discussed. This review has also made an effort to highlight the positive aspect of the foulant layer in retaining pharmaceuticals and antibiotic resistance genes, thereby suggesting a possible delicate trade-off between the flux decline and enhanced removal of pharmaceuticals.